SecBot SecBot

JNJ

JOHNSON & JOHNSON
NYSE· Pharmaceutical Preparations· Inc. NJ· CIK 0000200406 Biotech & Drug Discovery
$282.78 −2.97 (−1.04%)
Nov 16 4:00 PM ET · prev $285.75
Market cap
$682.8B
Mega cap
Consensus
Buy
70% Buy or better · 30 analysts
Median target
$280.50
−1% · range $190.00–320.00
1 year
+41.7%
from $199.58 · Nov 17
30 days
+10.7%
from $255.56
52-week range
$199.58–285.75
−1% from high · low Nov 17
Avg volume 20D
7.18M
shares / day
Short interest
17.07M
≈0.7% of shares · +1.8%
Days to cover
2.4
at average volume
Insider net
−$75.2M
0 buyers · 7 sellers · since Feb 9
New fund stakes
8
Q2 2026 13F · 1 exit
Reddit crowd
67°
Warm · 8 mentions this week
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 1 bullish · 2 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Feb 20 to Feb 27 ▼ 2 days of insider sells: $1.3M by 2 insiders, avg $247.33
  • Apr 14 ▲ Johnson & Johnson reported Q1 2026 earnings with adjusted EPS of $2.…
  • Jun 11 ▼ 1 insider sell $2.4M at $241.15
  • Jun 30 ▲ 8 funds open new positions (13F)
  • Jul 20 ▼ 1 insider sell $5.8M at $251.27
  • Aug 5 to Aug 17 ▼ 4 days of insider sells: $52.8M by 3 insiders, avg $260.28
  • Sep 2 ▼ 1 insider sell $9.2M at $274.74
  • Sep 4 to Sep 8 ▲ 2 buys: Ro Khanna, Lloyd Doggett bought, last disclosed Oct 9
  • Sep 24 Owens et al v. Johnson & Johnson et al
  • Sep 30 to Oct 7 ▼ 2 sells: Thomas Kean Jr, Ro Khanna sold, last disclosed Nov 9
  • Nov 3 Trial readout: Results Pending: Rilpivirine (Phase 2), completed 77d ago
  • Nov 12 ▼ 1 insider sell $3.7M at $284.39
  • Nov 16 New catalyst: subscribers see the details Unlock

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $75.2M.

  • InstitutionsBULLISH

    Q2 2026: 57 added (8 new), 32 trimmed or exited. Largest new: Hrt Financial $262.1M, Polar Capital Holdings $199.0M.

  • AnalystsBULLISH

    21 of 30 rate it Buy or better. Median target $280.50 (−1%).

  • Short sellersSTEADY

    Short interest +1.8% to 17.07M shares. 2.4 days to cover, ≈0.7% of shares.

  • TrendUPTREND

    6% above its 50-day average. New closing high $285.75 on Nov 13.

  • SocialQUIET

    Crowd 67° (warm) this week from 8 mentions: 4 bullish, 0 bearish. No setup is alerting. Excludes 1 subscriber-only day.

Who's buying

13F· Q2 2026
8
new positions
1
exit
$956.1M
in new stakes · top 6 shown
FundMoveSharesValue
PRICE T ROWE ASSOCIATES INC /MD/ADD22,996,878$5.8B
Capital World InvestorsADD15,215,015$3.9B
Fisher Asset Management, LLCADD13,307,056$3.4B
BARCLAYS PLCTRIM4,651,595$1.2B
CITIGROUP INCADD3,925,186$996.9M
MARSHALL WACE, LLPADD2,989,537$759.3M
Bahl & Gaynor LLCTRIM1,970,876$500.5M
Assenagon Asset Management S.A.ADD1,939,364$492.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

30 analysts
Buy 70% rate it Buy or better
Strong Buy7Buy14Hold9Sell0Strong Sell0
12-month targets · 22 analysts

Price is inside the target range. Median implies −1%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Oct 16, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Oct 15, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 14, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Oct 14, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Oct 14, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Oct 7, 2026Guggenheim
REITERATE
REITERATEBuy
Congressional trades
JNJ trades disclosed by members of Congress, with disclosure delay.
6 members · 9 buys / 17 sells
DateMemberType AmountDisclosed
Oct 7, 2026 Ro KhannaDHouse Spouse account · Johnson & Johnson SELL $100K–$250K Nov 5, 2026 +29d
Sep 30, 2026 Thomas Kean JrRHouse Johnson & Johnson SELL $1K–$15K Oct 30, 2026 +30d
Sep 25, 2026 Ro KhannaDHouse Spouse account · Johnson & Johnson BUY $1K–$15K Oct 7, 2026 +12d
Sep 8, 2026 Lloyd DoggettDHouse Johnson & Johnson BUY $1K–$15K Oct 5, 2026 +27d
Sep 4, 2026 Ro KhannaDHouse Spouse account · Johnson & Johnson BUY $15K–$50K Oct 7, 2026 +33d
Aug 27, 2026 Thomas Kean JrRHouse Johnson & Johnson SELL $1K–$15K Sep 12, 2026 +16d
Aug 20, 2026 John BoozmanRSenate Joint account · Johnson & Johnson SELL $1K–$15K Sep 11, 2026 +22d
Aug 7, 2026 Ro KhannaDHouse Child account · Johnson & Johnson SELL $1K–$15K Sep 4, 2026 +28d
Jul 30, 2026 Rich McCormickRHouse Johnson & Johnson SELL $1K–$15K Aug 14, 2026 +15d
Jul 20, 2026 Ro KhannaDHouse Spouse account · Johnson & Johnson BUY $1K–$15K Aug 7, 2026 +18d

Insider ledger

Form 4
$0
bought · 0 insiders
$75.2M
sold · 7 insiders
DateInsiderTypeValue
Nov 12, 2026
Forminard Elizabeth
EVP, Chief Legal Officer
Nov 12, 2026
EXERCISE$2.0M
Nov 12, 2026
Forminard Elizabeth
EVP, Chief Legal Officer
Nov 12, 2026
SELL$3.7M
Sep 8, 2026
HEWSON MARILLYN A
Director
Sep 8, 2026
AWARD$50.0K
Sep 8, 2026
Woods Eugene A.
Director
Sep 8, 2026
AWARD$37.5K
Sep 8, 2026
Pinto Daniel E
Director
Sep 8, 2026
AWARD$31.3K
Sep 2, 2026
Schmid Timothy
EVP, WW Chair, MedTech
Sep 2, 2026
EXERCISE$1.5M
Sep 2, 2026
Schmid Timothy
EVP, WW Chair, MedTech
Sep 2, 2026
SELL$3.0M
Sep 2, 2026
Schmid Timothy
EVP, WW Chair, MedTech
Sep 2, 2026
EXERCISE$3.4M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
17 drugs tracked · Drug pipeline →
Recent
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 13, 2026
Clinical Trial
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Phase 3 · COMPLETED
Nov 12, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company")…

Washington

Corporate Lobbying

146 lobbying filings and 12 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
17,068,289
shares short
+1.8%
vs prior settlement
2.4
days to cover
≈0.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 15, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
Nov 12, 2026 SEC
Elizabeth Forminard, an officer of Johnson & Johnson, filed a Form 144 notice of intent to sell 13,072 shares of…
144 · Impact 2/10
Nov 12, 2026 Insider
Forminard Elizabeth acquired via exercise 13,072 shares
EVP, Chief Legal Officer @ $151.41 ($2.0M)
Nov 12, 2026 Insider
Forminard Elizabeth sold 13,072 shares
EVP, Chief Legal Officer @ $284.39 ($3.7M)
Oct 13, 2026 SEC
JNJ reported Q3 2026 adjusted EPS of $2.59, a -11.2% miss vs consensus of $2.92, and revenue of $25.4B vs $26.43B…
8-K · Impact 6/10
Oct 7, 2026 Congress
Ro Khanna sell
$100,001 - $250,000 · House
Sep 30, 2026 Congress
Thomas Kean Jr sell
$1,001 - $15,000 · House
Reddit Mentions per day, 14 days
Crowd this week 67° Warm 4 bullish · 0 bearish
Mentions, 7 days 8 0 in posts · 8 in comments
Recent posts
Recent comments
All social signals and their track records

SecBot reports

21 filings · 4 bullish · 2 bearish · 3 mixed · 12 neutral
All JNJ filing & press-release reports (21)